<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        437-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KINZADO
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINEZOLID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1447.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Kinzado is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if Kinzado is suitable to treat your infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take</strong><strong> </strong><strong>Kinzado:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to linezolid or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These medications may be used to treat depression or Parkinson&rsquo;s disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are breastfeeding. This is because Kinzado passes into breast milk and could affect the baby.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Kinzado.</p><p>&nbsp;</p><p>Kinzado may not be suitable for you if you answer <strong>yes </strong>to any of the following questions. In this case tell your doctor as he/she will need to check your general health and your blood pressure before and during your treatment or may decide that another treatment is better for you.</p><p>&nbsp;</p><p>Ask your doctor if you are not sure whether these categories apply to you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do you have high blood pressure, whether or not you are taking medicines for this?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Have you been diagnosed with an overactive thyroid?</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do you have a tumour of the adrenal glands (phaeochromocytoma) or carcinoid syndrome (caused by tumours of the hormone system with symptoms of diarrhoea, flushing of the skin, wheezing)?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do you suffer from manic depression, schizoaffective disorder, mental confusion or other mental problems?</p><p>&nbsp;</p><p><strong>Take special care with Kinzado</strong></p><p><strong>&nbsp;</strong></p><p>Tell your doctor before you take this medicine if you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; bruise and bleed easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are anaemic(have low red blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; are prone to getting infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have a history of seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems or kidney problems particularly if you have dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; have diarrhoea.</p><p>&nbsp;</p><p>Tell your doctor immediately if during treatment you suffer from</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Loss of sensitivity in your arms or legs or a sensation of tingling or pricking in your arms or legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; you may develop diarrhoea while taking or after taking antibiotics, including Kinzado. If this becomes severe or persistent or you notice that your stool contains blood or mucus, you should stop taking Kinzado immediately and consult your doctor. In this situation, you should not take medicines that stop or slow bowel movement.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; recurrent nausea or vomiting, abdominal pain or over breathing.</p><p>&nbsp;</p><p><strong>Other medicines and Kinzado</strong></p><p><strong>&nbsp;</strong></p><p>There is a risk that Kinzado may sometimes interact with certain other medicines to cause side effects such as changes in blood pressure, temperature, or heart rate.</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.</p><p>&nbsp;</p><p><strong>Tell your doctor if you are taking or have taken within the last 2 weeks the </strong>following medicines as Kinzado <strong>must not </strong>be taken if you are already taking these medicines or have taken them recently. (See also Section 2 above &lsquo;<strong>Do not take </strong>Kinzado&rsquo;).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; monoamine oxidase inhibitors ( MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p>Also tell your doctor if you are taking the following medicines. Your doctor may still decide to give you Kinzado, but will need to check your general health and your blood pressure before and during your treatment. In other cases, your doctor may decide that another treatment is better for you.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Decongestant cold or flu remedies containing pseudoephedrine or phenylpropanolamine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat asthma such as salbutamol, terbutaline, fenoterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Certain antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors). There are many of these, including amitriptyline, citalopram, clomipramine,</p><p>&nbsp;</p><p>dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine, sertraline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat migraine such as sumatriptan and zolmitriptan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which increase your blood pressure, such as noradrenaline (norepinephrine), dopamine and dobutamine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat moderate to severe pain, such as pethidine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat anxiety disorders, such as buspirone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that stop blood clotting, such as warfarin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; An antibiotic called rifampicin.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Kinzado with food, drink and alcohol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; You can take Kinzado either before, during or after a meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Avoid eating large amounts of mature cheese, yeast extracts, or soya bean extracts e.g. soy sauce and drinking alcohol, especially draught beers and wine. This is because this medicine may react with a substance called tyramine which is naturally present in some foods to cause an increase in your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you develop a throbbing headache after eating or drinking, tell your doctor, pharmacist or nurse immediately.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>The effect of Kinzado in pregnant women is not known. Therefore, it should not be taken in pregnancy unless advised by your doctor. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>You should not breastfeed when using Kinzado because it passes into breast milk and could affect the baby.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Kinzado may make you feel dizzy or may impair your vision. If this happens, do not drive or operate any machinery.</p><p>Remember that if you are unwell your ability to drive or operate machinery may be affected.</p><p>&nbsp;</p><p><strong>Kinzado contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp; <strong>Adults</strong></p><p>Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure. The recommended dose is one film-coated tablet (600 mg linezolid) twice daily (every twelve hours). Swallow the film-coated tablet whole with some water.</p><p>&nbsp;</p><p>If you are on kidney dialysis, you should take Kinzado after dialysis treatment.</p><p>&nbsp;</p><p>A course of treatment usually lasts 10 to 14 days, but can last up to 28 days. The safety and effectiveness of this medicine have not been established for treatment periods longer than 28 days. Your doctor will decide how long you should be treated.</p><p>&nbsp;</p><p>While you are taking Kinzado, your doctor should perform regular blood tests to monitor your blood count.</p><p>&nbsp;</p><p>Your doctor should monitor your eyesight if you take Kinzado for more than 28 days.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>Kinzado is not normally used to treat children and adolescents (under 18 years old).</p><p>&nbsp;</p><p><strong>If you receive more Kinzado than you should</strong></p><p>Tell your doctor or pharmacist immediately.</p><p>&nbsp;</p><p><strong>If you forget to take Kinzado</strong></p><p>Take the forgotten tablet as soon as you remember. Take the next film-coated tablet 12 hours after this and continue taking your tablets every 12 hours. <strong>Do not take a double dose to make up for a forgotten dose.</strong></p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking Kinzado</strong></p><p>Unless your doctor instructs you to stop treatment, it is important to continue taking Kinzado.</p><p>If you stop and your original symptoms come back tell your doctor or pharmacist immediately.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side-effects although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor, nurse or pharmacist immediately </strong>if you notice any of these side effects during your treatment with Kinzado:</p><p>&nbsp;</p><p>The serious side effects (with frequency in brackets) of Kinzado are:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Severe skin disorder (not known), swelling particularly around the face and neck (not known), wheezing and/or difficulty breathing (not known). This may be the sign of an allergic reaction and it may be necessary for you to stop taking Kinzado. Skin reactions such as red sore skin and flaking (dermatitis) (uncommon), rash (common), itching (common).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; problems with your vision such as blurred vision (uncommon), changes in colour vision (not known), difficulty in seeing detail (not known) or if your field of vision becomes restricted (rare).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; severe diarrhoea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which in rare circumstances may develop into complications that are life-threatening (rare).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; recurrent nausea or vomiting, abdominal pain or rapid breathing (not known).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fits or seizures (uncommon) have been reported with Kinzado. You should let your doctor know if you experience agitation, confusion, delirium, rigidity, tremor,</p><p>&nbsp;</p><p>incoordination and seizure while also taking antidepressants known as SSRI&rsquo;s (selective serotonin reuptake inhibitors) (see section 2) (not known).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Unexplained bleeding or bruising, which may be due to changes in the numbers of certain cells in the blood which may affect blood clotting or lead to anaemia (common).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in numbers of certain cells in the blood which may affect your ability to fight infection (common) some signs of infection include: any fever (common), sore throat (uncommon), mouth ulcers (uncommon) and tiredness (uncommon).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas (uncommon).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions (uncommon).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Transient ischaemic attacks (temporary disturbance of blood flow to the brain causing short term symptoms such as loss of vision, leg and arm weakness, slurring of speech and loss of consciousness) (uncommon).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; &quot;Ringing&quot; in the ears (tinnitus) (uncommon).</p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common side-effects (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections especially vaginal or oral &ldquo;thrush&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Metallic taste in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea or vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some blood test results including those measuring your kidney or liver function or blood sugar levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low red blood cell)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Localised or general abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Localised pain</p><p>&nbsp;</p><p><strong>Uncommon side-effects (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the vagina or genital area in women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sensations such as tingling or feeling numb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the veins (IV only)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swollen, sore, or discoloured tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; A need to urinate more often</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Feeling thirsty</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in proteins, salts or enzymes in the blood which measure kidney or liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatraemia (low blood sodium levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in platelets</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal bloating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Injection site pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increase in creatinine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in heart rate (e.g., increase rate)</p><p>&nbsp;</p><p><strong>Rare side-effects (may affect up to 1 in 1000 people)<em>:</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Superficial tooth discolouration, removable with professional dental cleaning (manual descaling)</p><p>&nbsp;</p><p><strong>The following side effects have also been reported (Not known: frequency cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia (hair loss)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of the blood cell count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Weakness and/or sensory changes</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children. Do not Store above 30 &deg;C.</p><p>This medicinal product does not require any special storage conditions.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the carton, blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is called linezolid. Each film-coated tablet contains 600 mg</p><p>linezolid.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients:</strong></p><p>Kolliphor P 407 micro, Sodium Starch Glycollate, Povidone 30, Colloidal Silicon Dioxide, Avicel PH 102, Lactose NF Fast Flow-BMS 35957, Purified Talc, Magnesium Stearate.</p><p><strong>Coating materials: (Opadry II 33G28435 White)</strong></p><p>Hypromellose, Titanium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dioxide, Polyethylene&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glycol/Macrogol, Lactose Monohydrate, Triacetin, Purified Water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Kinzado 600 mg tablets are White to off-white, oval shaped, film-coated tablets, engraved with "600" on one side and plain on the other side.
 
Kinzado tablets are available as PVC/PE/PVDC -Aluminium foil blisters. Each carton contains 10 tablets (10 tablets/1 Blister).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2021.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">كينزادو هو مضاد حيوي من مجموعة أوكسازوليدينونيس الذي يعمل عن طريق وقف نمو بعض البكتيريا )الجراثيم(<br />التي تسبب العدوى. يتم استخدامه لعلاج الالتهاب الرئوي وبعض الالتهابات في الجلد أو تحت الجلد. سوف يقرر<br />طبيبك إذا كان كينزادو مناسب لعلاج العدوى الخاصة بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا تتناول كين زادو فى الحالات الآتية :</strong><br />.) &bull; إذا كان لديك حساسية من لينزوليد أو أي من المكونات الأخرى من هذا الدواء )المذكورة في الفقرة 6<br />&bull; إذا كنت تتناول أو قد تناولت في غضون الأسبوعين الماضيين أي أدوية تعرف باسم مثبطات مونوامين أوكسيديز<br />على سبيل المثال )فينيلزين، إيزوكاربوكسازيد، سيليجيلين، موكلوبيميد(. وتستخدم هذه الأدوية لعلاج الاكتئاب<br />أو مرض باركنسون.<br />&bull; إذا كنت ترضعين طفلك رضاعة طبيعية. وذلك لأن كينزادو يمر في حليب الثدي ويمكن أن يؤثر على صحة<br />الطفل .</p><p dir="RTL"><br /><strong>المحاذير والاحتياطات</strong><br />تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تناول كينزادو<br />كينزادو قد لا يكون مناسب لك إذا أجبت بنعم على أي من الأسئلة التالية. في هذه الحالة أخبر طبيبك بأنه / أنها سوف<br />تحتاج إلى التحقق من صحتك العامة وضغط الدم قبل وأثناء العلاج أو قد يقرر أن علاج آخر هو أفضل بالنسبة لك .<br />اسأل طبيبك إذا لم تكن متأكدا مما إذا كانت هذه الفئات تنطبق عليك.</p><p dir="RTL">&bull; هل تعاني من ارتفاع ضغط الدم، سواء كنت تتناول أدوية أم لا؟<br />&bull; هل تم تشخيصك بنشاط الغدة الدرقية المفرط ؟<br />&bull; هل لديك ورم في الغدد الكظرية )ورم القواتم( أو متلازمة السرطاوي )التي تسببها أورام أنظمة الهرمونات مع<br />أعراض الإسهال، احمرار الجلد، والتنفس(؟<br />&bull; هل تعاني من الاكتئاب، الهوس، اضطراب الفصام، الارتباك العقلي أو غيرها من المشاكل العقلية ؟<br />&nbsp;</p><p dir="RTL"><strong>أعطي عناية خاصة مع كينزادو</strong><br />أخبر طبيبك قبل أن يتم وصف هذا الدواء لك إذا كنت<br />&bull; لديك كدمات ونزيف بسهولة<br />&bull; تعاني من فقر الدم )لديك خلايا الدم الحمراء منخفضة(<br />&bull; أكثر عرضة للعدوى<br />&bull; لديك تاريخ من نوبات الصرع<br />&bull; لديك مشاكل في الكبد أو مشاكل في الكلى خاصة في حالة غسيل الكلى<br />&bull; لديك إسهال.</p><p dir="RTL"><strong>أخبر طبيبك فورا إذا كنت تعاني أثناء العلاج من</strong><br />&bull; مشاكل في رؤيتك مثل عدم وضوح الرؤية، والتغيرات في رؤية اللون، وصعوبة في رؤية التفاصيل أو إذا كان<br />مجال الرؤية الخاصة بك أصبح محدودا.<br />&bull; فقدان الحساسية في ذراعيك، أو ساقيك، أو الإحساس بالوخز، أو الخز في ذراعيك أو ساقيك.<br />&bull; قد تتعرض للإسهال مع تناول أو بعد تناول المضادات الحيوية، بما في ذلك كينزادو. إذا أصبح هذا شديد أو مستمر<br />أو لاحظت أن البراز يحتوي على دم أو مخاط، يجب عليك التوقف عن تناول كينزادو فورا واستشارة الطبيب. في<br />هذه الحال ة، يجب ألا تتناول الأدوية التي توقف أو تبطئ حركة الأمعاء.<br />&bull; الغثيان المتكرر أو القيء، وآلام في البطن أو زيادة معدل التنفس.</p><p dir="RTL"><strong>أدوية أخرى وكينزادو</strong><br />هناك خطر أن كينزادو قد يتفاعل أحيانا مع بعض الأدوية الأخرى مما يؤدي إلى آثار جانبية مثل التغيرات في ضغط<br />الدم، درجة الحرارة أو معدل ضربات القلب.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت في الآونة الأخيرة أي أدوية أخري .</p><p dir="RTL"><strong>أخبر طبيبك إذا كنت تتناول أو تناولت في الأسبوعين الأخيرين الأدوية التالية لأن كينزادو يجب ألا يتم تناوله </strong>إذا<br />كنت تتناول بالفعل هذه الأدوية أو تناولتها مؤخرا. )انظر أيضا القسم 2 أعلاه <strong>&quot;يجب ألا تتناول كينزادو&quot;</strong>(.</p><p dir="RTL"><br />&bull; مثبطات مونوامين أوكسيديز على سبيل المثال فينيلزين، إيزوكاربوكسازيد، سيليجيلين، موكلوبيميد . ويمكن<br />استخدام هذه لعلاج الاكتئا ب أو م رض باركنسون.<br />أخبر طبيبك أيضا إذا كنت تتناول الأدوية التالية. قد يقرر طبيبك أن يعطيك كينزادو، ولكن سيحتاج إلى التحقق من صحتك<br />العامة وضغط الدم قبل وأثناء العلاج. في حالات أخرى، قد يقرر طبيبك أن علاج آخر هو أفضل بالنسبة لك:<br />&bull; مزيلات الاحتقان، أدوية علاج البرد أو الانفلونزا التي تحتوي على السودوإيفيدرين أو فينيلبروبانولامين.<br />&bull; الأدوية المستخدمة لعلاج الربو مثل السالبوتامول، تيربوتالين، فينوتيرول؛</p><p dir="RTL">&bull; مضادات الاكتئاب المعروفة باسم ثلاثية الحلقات أو اس اس اراي )مثبطات امتصاص السيروتونين<br />الانتقائية( على سبيل المثال أميتريبتيلين، سيتالوبرام، كلوميبرامين، دوسيلوبين، دوكسيبين، فلوكستين،<br />فلوفوكسامين، إيميبرامين، لوفيبرامين، الباروكستين. سيرترالين؛<br />&bull; الأدوية المستخدمة لعلاج الصداع النصفي مثل سوماتريبتان وزولميتريبتان.<br />&bull; الأدوية المستخدمة لعلاج الحساسية المفاجئة والحادة مثل الأدرينالين )ادرينالين(.<br />&bull; الأدوية التي تزيد من ضغط الدم، مثل نورادرينالين )النورابينفرين(، الدوبامين والدوبوتامين.<br />&bull; الأدوية المستخدمة لعلاج الألم المعتدل إلى الشديد، مثل البيثيدين.<br />&bull; الأدوية المستخدمة لعلاج اضطرابات القلق، مثل بسبيرون؛<br />&bull; الأدوية التي تستخدم لوقف تجلط الدم مثل وارفاري ن<br />&bull; مضاد حيوي يسمى ريفامبيسين.</p><p dir="RTL"><strong>كينزادو مع الطعام والشراب والكحول</strong><br />&bull; يمكنك أن تتناول كينزادو سواء قبل أو أثناء أو بعد الوجبة الغذائية.<br />&bull; تجنب تناول كميات كبيرة من الجبن الناضج أو مقتطفات الخميرة أو مستخلصات فول الصويا مثل صلصة<br />الصويا أو شرب الكحول، وخاصة البيرة والنبيذ. وذلك لأن هذا الدواء قد يتفاعل مع مادة تسمى تيرامين<br />التي توجد بشكل طبيعي في بعض الأطعمة لتسبب زيادة في ضغط الدم.<br />&bull; إذا كنت تعاني من صداع، خفقان بعد تناول الطعام أو الشراب، أخبر طبيبك أو الصيدلي أو الممرضة فورا .</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong><br />تأثير كينزادو في النساء الحوامل غير معروف. لذلك لا ينبغي أن يتم استخدامه في الحمل إلا إذا نصحك الطبيب بذلك.<br />إذا كنت حاملا، أو مرضعة، تعتقدين أنك قد تكون حاملا أو تخطط ين للإنجاب، اطلبي من الطبيب أو الصيدلي<br />الحصول على المشورة قبل تناو ل هذا ا لدواء .<br />يجب الامتناع عن الرضاعة الطبيعية عند استخدام كينزادو لأنه يمر في حليب الثدي ويمكن أن يؤثر على الطفل.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />كينزادو قد يجعلك تشعر بالدوار، قد يضعف الرؤية الخاصة بك. إذا حدث هذا، لا تدفع أو تشغل الآلات.<br />تذكر أنه إذا كنت تشعر أنك لست على ما يرام قد تتأثر قدرتك على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>كينزادو يحتوي على لاكتوز</strong><br />إذا تم إبلاغك من قبل الطبيب المعالج بعدم تحملك لبعض أنواع السكر، تواصل مع طبيبك المعالج قبل البدء فى تناول<br />هذا الدواء .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>للبالغين</strong><br />قم دائما بتناول الدواء تمام ا كما تم وصفه في النشرة أو كما أخبرك طبيبك المعالج أو الصيدلي أو الممرضة. تحقق من<br />خلال طبيبك المعالج أو الصيدل ي أو الممرضة إذا لم تكن متأكداً. الجرعة الموصي بها من أقراص كينزادو المغلفة<br />بطبقة رقيقة ) 600 ملجم من المادة الفعالة لينزوليد( مرتين ي وميا )كل 12 ساعة(. ابتلع القرص المغلف بطبقة رقيقة<br />بالكامل مع بعض الماء.<br />إذا كنت تقوم ب غسيل الكلى، يجب أن تعطى كينزادو بعد غسيل الكلى.<br />دورة العلاج عادة ما تستغرق 10 إلى 14 يوما، ولكن يمكن أن تستمر لمدة تصل إلى 28 يوما. لم يتم اختبار سلامة<br />وفعالية هذا الدواء لفترات عالج أطول من 28 يوما. سوف يقرر طبيبك المدة التي يجب أن تعالج فيها.<br />أثناء تناولك كينزادو، يجب على طبيبك إجراء فحوص دم منتظمة لمراقبة صورة دمك.<br />يجب على الطبيب مراقبة نظرك إذا كنت تتناول كينزادو لأكثر من 28 يوما.</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong><br />كينزادو لا يستخدم عادة لعلاج الأطفال والمراهقين )تحت سن 18 سنة(.</p><p dir="RTL"><strong>إذا تناولت كينزادو أكثر مما يجب</strong><br />أخبر طبيبك أو الصيدلى فور اً .</p><p dir="RTL"><strong>إذا نسيت تناول جرعة من كينزادو</strong><br />قم بتناول الجرعة المنسية حالما تتذكرها. ثم تناول الجرعة التالية بعد 12 ساعة ثم استمر فى تناول الجرعات كل 12<br />ساعة. <strong>لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية .</strong></p><p dir="RTL"><strong>فى حالة التوقف عن تناول أقراص كينزادو</strong><br />من الضرورى الحرص على تناول أقراص كينزادو ما لم يخبرك طبيب ك المعالج بغير ذلك. إذا توقفت عن تناول<br />الدواء ثم عادت إليك أعراضك الأصلية أخبر طبيبك المعالج أو الصيدلى فى الحال .<br />إذا كانت لديك أسئلة إضافية بشأن تناول هذا الدواء، اسأل طبيبك المعالج أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، يمكن أن يسبب هذا الدواء آثارا جانبية على الرغم من عدم تعرض الجميع لها.<br /><strong>أخبر طبيبك أو الممرضة أو الصيدلي فورا </strong>إذا لاحظت أي من هذه الآثار الجانبية أثناء العلاج مع كينزادو:</p><p dir="RTL">الأعراض الجانبية الخطيرة )مع شيوعها بين قوسين( ل كينزادو هي:<br />&bull; اضطراب جلدي حاد )غير معروف(، انتفاخ خاصة حول الوجه والرقبة )غير معروف(، أزيز و / أو صعوبة<br />في التنفس )غير معروف(. قد تكون هذه علامة لرد فعل تحسسي وقد يكون من الضروري بالنسبة لك التوقف عن<br />تناول كينزادو. تفاعلات جلدية مثل التهاب الجلد الأحمر والتقشر )التهاب الجلد( )غير شائع(، الطفح الجلدي )شائع(،<br />الحكة )شائعة(.<br />&bull; مشاكل في رؤيتك مثل عدم وضوح الرؤية )غير شائع( ، والتغيرات في رؤية اللون )غير معروف( ، وصعوبة<br />في رؤية التفاصيل )غير معروف( أو إذا كان مجال الرؤية الخاصة بك أصبح محدودا )نادر( .<br />&bull; الإسهال الشديد الذي يحتوي على الدم و / أو المخاط )التهاب القولون المصاحب للمضادات الحيوية ومنها التهاب<br />القولون الغشائي الكاذب(، والتي في حالات نادرة قد تتطور إلى مضاعفات قد تهدد الحياة )نادر(.<br />&bull; الغثيان المتكرر أو التقيؤ، آلام في البطن أو زيادة معدل التنفس )غير معروف(.<br />&bull; تم الإبلاغ عن نوبات تشنج أو صرع )غير شائع( مع كينزادو. يجب أن تدع طبيبك يعرف إذا كنت تعرضت<br />لحالة من الارتباك، أو الهياج، أو الهذيان، أو التصلب، أو رعاش، أيضا نوبات وعدم تناسق أثناء تناول مضادات<br />الاكتئاب المعروفة باسم )مثبطات امتصاص السيروتونين الانتقائية( )انظر القسم 2( )غير معروف(.<br />&bull; نزيف أو كدمات غير مبررة، والتي قد تكون بسبب التغيرات في عدد خلايا معينة في الدم والتي قد تؤثر على<br />تخثر الدم أو تؤدي إلى فقر الدم )شائع(.<br />&bull; التغيرات في عدد خلايا معينة في الدم والتي قد تؤثر على قدرتك على مقاومة العدوى )شائعة( وتشمل بعض<br />علامات العدوى: أي حمى )شائعة(، والتهاب الحلق )غير شائع(، وتقرحات في الفم )غير شائعة(، وإرهاق )غير<br />شائع(.<br />&bull; التهاب البنكرياس )غير شائع(.<br />&bull; التشنجات )غير شائ عة(.<br />&bull; نوبات إقفاريه عابرة )اضطراب مؤقت في تدفق الدم إلى الدماغ يسبب أعراضًا قصيرة المدى مثل فقدان البصر<br />وضعف الساق والذراع وصعوبة في الكلام وفقدان الوعي( )غير شائع(.<br />&bull; &quot;رنين&quot; في الأذنين )طنين( )غير شائع(.</p><p dir="RTL"><strong>وتشمل الأعراض الجانبية الأخرى:<br />الأعراض الجانبية الشائعة )قد تصيب أقل من 1 من كل 10 أشخاص(:</strong><br />&bull; الالتهابات الفطرية خاصة المهبلية أو الفموية &quot;القلاع &quot;<br />&bull; صداع الرأس<br />&bull; طعم معدني في الفم<br />&bull; الإسهال، والغثيان أو القيء<br />&bull; التغيرات في بعض نتائج اختبار الدم بما في ذلك تلك التي تقيس وظائف الكلى أو وظيفة الكبد أو مستويات السكر<br />في الد م<br />&bull; صعوبة النوم<br />&bull; ارتفاع ضغط الدم<br />&bull; فقر الدم )خلايا الدم الحمراء منخفضة(<br />&bull; دوار<br />&bull; آلام البطن الموضعية أو العام ة<br />&bull; إمساك<br />&bull; عسر الهض م<br />&bull; ألم موضعي</p><p dir="RTL"><strong>أعراض جانبية غير شائعة )قد تصيب أقل من 1 من 100 شخص(:</strong><br />&bull; التهاب المهبل أو منطقة الأعضاء التناسلية لدى النسا ء<br />&bull; أحاسيس مثل الوخز أو الشعور بالخد ر<br />&bull; التهاب الأوردة )عن طريق الوريد فقط(<br />&bull; اللسان المتورم أو المتقرح أو المشوه<br />&bull; الحاجة إلى التبول في كثير من الأحيان<br />&bull; قشعريرة<br />&bull; الشعور بالعطش<br />&bull; زيادة التعرق<br />&bull; التغيرات في البروتينات والأملاح أو الإنزيمات في الدم التي تقيس وظائف الكلى أو الكبد<br />&bull; نقص صوديوم الدم )انخفاض مستويات الصوديوم في الدم(<br />&bull; فشل كلوي<br />&bull; انخفاض في عدد الصفائح الدموية<br />&bull; انتفاخ البطن<br />&bull; ألم موقع الحق ن<br />&bull; زيادة الكرياتينين<br />&bull; آلام في المعدة<br />&bull; التغيرات في معدل ضربات القلب )مثل زيادة معدل ضربات القلب(</p><p dir="RTL"><strong>أعراض جانبية نادرة ) قد تصيب أقل من 1 في 1000 شخص(:</strong><br />&bull; تلون الأسنان السطحي، يمكن إزالته بتنظيف الأسنان الاحترافي )إزالة الترسبات يدويا(</p><p dir="RTL"><strong>كما تم الإبلاغ عن الأعراض الجانبية التالية )غير معروف: لا يمكن تقدير الشيوع من البيانات المتاحة(:</strong><br />&bull; صلع )تساقط الشعر(<br />&bull; انخفاض عدد خلايا الد م</p><p dir="RTL">&bull; الضعف و / أو التغيرات الحسي ة</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض<br />جانبية محتملة غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني<br />للتيقظ والسلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات<br />حول سلامة هذا الدواء.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول ونظر الأطفال<br />لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.<br />لا يتطلب هذا الدواء شروط معينة للتخزين .<br />تاريخ .&ldquo;EXP&rdquo; لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدرج على الكرتونة، والشريط بعد كلمة<br />الصلاحية يشير إلى آخر يوم فى الشهر المذكور.<br />لا تقم بالتخلص من الأدوية عبر النفايات المنزلية ومياه الصرف الصحى. اسأل الصيدلى عن كيفية التخلص من<br />الأدوية التى لم تعد بحاجة إليها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; المادة الفعالة هي لينزوليد. كل قرص مغلف بطبقة رقيقة يحتوي على 600 ملجم من مادة لينزوليد.<br /><strong>&bull; المكونات الأخرى هي:</strong><br />PH المصغر، جليكولات نشا الصوديوم، بوفيدون 30 ، ثاني أكسيد السيليكون الغرواني، أفيسل P كوليفور 407<br />التلك المنقى، ستيرات الماغنيسيوم. ،BMS سريع التدفق- 35957 NF 102 ، لاكتوز</p><p dir="RTL"><strong>لأبيض( II 33G مكونات غلاف القرص : )أوبادري 28435</strong><br />هايبروم يلوز، ثاني أكسيد التيتانيوم، بولي إيثيلين جلايكول/ماكرو جول، لاكتوز أحادي التموه، تراياسيتين، ماء<br />منقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص كينزادو 600 ملجم هي أقراص ذات لون أبيض إلى أبيض مطفي، بيضاوية الشكل، مغلفة بطبقة رقيقة،<br />محفورة ب &quot; 600 &quot; على أحد ال جانبين وخالبة من العلامات على الجانب الأخر. تتوفر أقراص كينزادو في شرائط من<br />.PVC/PE/PVDC الألومنيوم<br />كل علبة تحتوي على 10 أقراص مغلفة بطبقة رقيقة ) 10 أقراص / شريط واحد(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الدوائية<br />مصنع الأدوية بالقصيم،<br />المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2021 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Kinzado 600 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 600 mg of linezolid. Excipient with known effect:
Each film-coated contains 25.2 mg of lactose monohydrate. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

White to off-white, oval shaped, film-coated tablet, engraved with "600" on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp; </strong>Nosocomial pneumonia Community acquired pneumonia</p><p>Kinzado is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible Gram-positive bacteria. In determining whether Kinzado is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among Gram positive bacteria should be taken into consideration. (See section 5.1 for the appropriate organisms).</p><p>&nbsp;</p><p>Kinzado is not active against infections caused by Gram negative pathogens. Specific therapy against Gram negative organisms must be initiated concomitantly if a Gram-negative pathogen is documented or suspected.</p><p>&nbsp;</p><p>Complicated skin and soft tissue infections (see section 4.4)</p><p>&nbsp;</p><p>Kinzado is indicated for the treatment of complicated skin and soft tissue infections <strong>only </strong>when microbiological testing has established that the infection is known to be caused by susceptible Gram-positive bacteria.</p><p>&nbsp;</p><p>Kinzado is not active against infections caused by Gram negative pathogens. Kinzado should only be used in patients with complicated skin and soft tissue infections with known or possible co- infection with Gram negative organisms if there are no alternative treatment options available (see section 4.4). In these circumstances treatment against Gram negative organisms <u>must</u> be initiated concomitantly.</p><p>&nbsp;</p><p>Kinzado should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious diseases specialist.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>[Linezolid] solution for infusion, film-coated tablets or oral suspension may be used as initial therapy. Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as linezolid has an oral bioavailability of approximately 100%.</p><p>&nbsp;</p><p><strong><em>Recommended dosage and duration of treatment for adults: </em></strong>The duration of treatment is dependent on the pathogen, the site of infection and its severity, and on the patient&#39;s clinical response.</p><p>&nbsp;</p><p>The following recommendations for duration of therapy reflect those used in the clinical trials. Shorter treatment regimens may be suitable for some types of infection but have not been evaluated in clinical trials.</p><p>&nbsp;</p><p>The maximum treatment duration is 28 days. The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established. (see section 4.4).</p><p>&nbsp;</p><p>No increase in the recommended dosage or duration of treatment is required for infections associated with concurrent bacteraemia.</p><p>&nbsp;</p><p>The dose recommendation for the solution for infusion and the tablets/granules for oral suspension are identicalare as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Infections</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td><td rowspan="2" style="vertical-align:top"><p>600 mg twice daily</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>10-14 Consecutive days</p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>600 mg twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Paediatric population:</p><p>The safety and efficacy of linezolid in children aged (&lt; 18 years old) has not been established. Currently available data are described in section 4.8, 5.1, and 5.2 but no recommendation on a posology can be made</p><p>&nbsp;</p><p><strong><em>Elderly patients</em></strong>: No dose adjustment is required.</p><p>&nbsp;</p><p><strong><em>Patients with renal impairment: </em></strong>No dose adjustment is required (see sections 4.4 and 5.2). <u>Severe renal impairment (i.e., CL</u><u>CR </u><u>&lt; 30 ml/min)</u>:</p><p>No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10-fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk.</p><p>&nbsp;</p><p>As approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.</p><p>&nbsp;</p><p>Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis and only when the anticipated benefit is considered to outweigh the theoretical risk.</p><p>&nbsp;</p><p>To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis).</p><p>&nbsp;</p><p>Patients with hepatic impairment:</p><p>No dose adjustment is required. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Method of administration:</u></p><p>&nbsp;</p><p>The recommended linezolid dosage should be administered orally twice daily. Route of administration: Oral use.</p><p>The film-coated tablets may be taken with or without food.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to linezolid or to any of the excipients listed in section 6.1.

Kinzado should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. phenelzine, isocarboxazid, selegiline, moclobemide) or within two weeks of taking any such medicinal product.

Unless there are facilities available for close observation and monitoring of blood pressure, linezolid should not be administered to patients with the following underlying clinical conditions or on the following types of concomitant medications:

-	Patients with uncontrolled hypertension, phaeochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder, acute confusional states.
-	Patients taking any of the following medications: serotonin re-uptake inhibitors (see section 4.4), tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), directly and indirectly acting sympathomimetic agents (including the adrenergic bronchodilators, pseudoephedrine and phenylpropanolamine), vasopressive agents (e.g. epinephrine, norepinephrine), dopaminergic agents (e.g. dopamine, dobutamine), pethidine or buspirone.

Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breastfeeding should be discontinued prior to and throughout administration (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Myelosuppression</em></p><p><em>&nbsp;</em></p><p>Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected haematologic parameters have risen toward pretreatment levels. The risk of these effects appears to be related to the duration of treatment. Elderly patients treated with linezolid may be at greater risk of experiencing blood dyscrasias than younger patients. Thrombocytopenia may occur more commonly in patients with severe renal insufficiency, whether or not on dialysis. Therefore, close monitoring of blood counts is recommended in patients who: have pre-existing anaemia, granulocytopenia or thrombocytopenia; are receiving concomitant medications that may decrease haemoglobin levels, depress blood counts or adversely affect platelet count or function; have severe renal insufficiency; receive more than 10-14 days of therapy. Linezolid should be administered to such patients only when close monitoring of haemoglobin levels, blood counts and platelet counts is possible.</p><p>&nbsp;</p><p>If significant myelosuppression occurs during linezolid therapy, treatment should be stopped unless it is considered absolutely necessary to continue therapy, in which case intensive monitoring of blood counts and appropriate management strategies should be implemented.</p><p>&nbsp;</p><p>In addition, it is recommended that complete blood counts (including haemoglobin levels, platelets, and total and differentiated leucocyte counts) should be monitored <u>weekly</u> in patients who receive linezolid regardless of baseline blood count.</p><p>&nbsp;</p><p>In compassionate use studies, a higher incidence of serious anaemia was reported in patients receiving linezolid for more than the maximum recommended duration of 28 days. These patients more often required blood transfusion. Cases of anaemia requiring blood transfusion have also been reported post marketing, with more cases occurring in patients who received linezolid therapy for more than 28 days.</p><p>&nbsp;</p><p>Cases of sideroblastic anaemia have been reported post-marketing. Where time of onset was known, most patients had received linezolid therapy for more than 28 days. Most patients fully or partially recovered following discontinuation of linezolid with or without treatment for their anaemia.</p><p>&nbsp;</p><p><em>Mortality imbalance in a clinical trial in patients with catheter-related Gram-positive bloodstream infections</em></p><p><em>&nbsp;</em></p><p>Excess mortality was seen in patients treated with linezolid, relative to vancomycin/dicloxacillin/oxacillin, in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs 58/363 (16.0%)]. The main factor influencing the mortality rate was the Gram-positive infection status at baseline. Mortality rates were similar in patients with infections caused purely by Gram positive organisms (odds ratio 0.96; 95% confidence interval: 0.58-1.59) but were significantly higher (p=0.0162) in the linezolid arm in patients with any other pathogen or no pathogen at baseline (odds ratio 2.48; 95% confidence interval: 1.38-4.46). The greatest imbalance occurred during treatment and within 7 days following discontinuation of study drug. More patients in the linezolid arm acquired Gram negative pathogens during the study and died from infection caused by Gram negative pathogens and polymicrobial infections. Therefore, in complicated skin and soft tissue infections linezolid should only be used in patients with known or possible co-infection with Gram negative organisms if there are no</p><p>&nbsp;</p><p>alternative treatment options available (see section 4.1). In these circumstances treatment against Gram negative organisms must be initiated concomitantly.</p><p>&nbsp;</p><p><em>Antibiotic-associated diarrhoea and colitis</em></p><p><em>&nbsp;</em></p><p>Antibiotic-associated diarrhoea and antibiotic-associated colitis, including pseudomembranous colitis and <em>Clostridium difficile</em>-associated diarrhoea, has been reported in association with the use of nearly all antibiotics including linezolid and may range in severity from mild diarrhoea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of linezolid. If antibiotic-associated diarrhoea or antibiotic- associated colitis is suspected or confirmed, ongoing treatment with antibacterial agents, including linezolid, should be discontinued and adequate therapeutic measures should be initiated immediately. Drugs inhibiting peristalsis are contraindicated in this situation.</p><p>&nbsp;</p><p><em>Lactic acidosis</em></p><p><em>&nbsp;</em></p><p>Lactic acidosis has been reported with the use of linezolid. Patients who develop signs and symptoms of metabolic acidosis including recurrent nausea or vomiting, abdominal pain, a low bicarbonate level, or hyperventilation while receiving linezolid should receive immediate medical attention. If lactic acidosis occurs, the benefits of continued use of linezolid should be weighed against the potential risks.</p><p>&nbsp;</p><p><em>Mitochondrial dysfunction</em></p><p><em>&nbsp;</em></p><p>Linezolid inhibits mitochondrial protein synthesis. Adverse events, such as lactic acidosis, anaemia and neuropathy (optic and peripheral), may occur as a result of this inhibition; these events are more common when the drug is used longer than 28 days.</p><p>&nbsp;</p><p><em>Serotonin syndrome</em></p><p><em>&nbsp;</em></p><p>Spontaneous reports of serotonin syndrome associated with the co-administration of linezolid and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) have been reported. Co-administration of linezolid and serotonergic agents is therefore contraindicated (see section 4.3) except where administration of linezolid and concomitant serotonergic agents is essential. In those cases patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia and incoordination. If signs or symptoms occur physicians should consider discontinuing either one or both agents; if the concomitant serotonergic agent is withdrawn, discontinuation symptoms can occur.</p><p>&nbsp;</p><p><em>Peripheral and optic neuropathy</em></p><p><em>&nbsp;</em></p><p>Peripheral neuropathy, as well as optic neuropathy and optic neuritis sometimes progressing to loss of vision, have been reported in patients treated with Kinzado; these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days.</p><p>&nbsp;</p><p>All patients should be advised to report symptoms of visual impairment, such as changes in visual acuity, changes in colour vision, blurred vision, or visual field defect. In such cases, prompt evaluation is recommended with referral to an ophthalmologist as necessary. If any patients are taking Kinzado for longer than the recommended 28 days, their visual function should be regularly monitored.</p><p>&nbsp;</p><p>If peripheral or optic neuropathy occurs, the continued use of Kinzado should be weighed against the potential risks.</p><p>&nbsp;</p><p>There may be an increased risk of neuropathies when linezolid is used in patients currently taking or who have recently taken antimycobacterial medications for the treatment of tuberculosis.</p><p>&nbsp;</p><p><em>Convulsions</em></p><p>Convulsions have been reported to occur in patients when treated with Kinzado. In most of these cases, a history of seizures or risk factors for seizures was reported. Patients should be advised to inform their physician if they have a history of seizures.</p><p>&nbsp;</p><p><em>Monoamine oxidase inhibitors</em></p><p><em>&nbsp;</em></p><p>Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI); however, at the doses used for antibacterial therapy, it does not exert an anti-depressive effect. There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients with underlying conditions and/or on concomitant medications which might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p><em>Use with tyramine-rich foods</em></p><p><em>&nbsp;</em></p><p>Patients should be advised against consuming large amounts of tyramine rich foods (see section 4.5).</p><p>&nbsp;</p><p><em>Superinfection</em></p><p><em>&nbsp;</em></p><p>The effects of linezolid therapy on normal flora have not been evaluated in clinical trials.</p><p>&nbsp;</p><p>The use of antibiotics may occasionally result in an overgrowth of non-susceptible organisms. For example, approximately 3% of patients receiving the recommended linezolid doses experienced drug-related candidiasis during clinical trials. Should superinfection occur during therapy, appropriate measures should be taken.</p><p>&nbsp;</p><p><em>Special populations</em></p><p><em>&nbsp;</em></p><p>Linezolid should be used with special caution in patients with severe renal insufficiency and only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p>It is recommended that linezolid should be given to patients with severe hepatic insufficiency only when the perceived benefit outweighs the theoretical risk (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><em>Impairment of fertility</em></p><p><em>&nbsp;</em></p><p>Linezolid reversibly decreased fertility and induced abnormal sperm morphology in adult male rats at exposure levels approximately equal to those expected in humans; possible effects of linezolid on the human male reproductive system are not known (see section 5.3).</p><p>&nbsp;</p><p><em>Clinical trials</em></p><p><em>&nbsp;</em></p><p>The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established.</p><p>&nbsp;</p><p>Controlled clinical trials did not include patients with diabetic foot lesions, decubitus or ischaemic lesions, severe burns or gangrene. Therefore, experience in the use of linezolid in the treatment of these conditions is limited.</p><p>&nbsp;</p><p><em>Lactose: </em>The tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Monoamine oxidase inhibitors</em></p><p><em>&nbsp;</em></p><p>Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI). There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients on concomitant medications that might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Potential interactions producing elevation of blood pressure</em></p><p><em>&nbsp;</em></p><p>In normotensive healthy volunteers, linezolid enhanced the increases in blood pressure caused by pseudoephedrine and phenylpropanolamine hydrochloride. Co-administration of linezolid with either pseudoephedrine or phenylpropanolamine resulted in mean increases in systolic blood pressure of the order of 30-40 mmHg, compared with 11-15 mmHg increases with linezolid alone, 14-18 mmHg with either pseudoephedrine or phenylpropanolamine alone and 8-11 mmHg with placebo. Similar studies in hypertensive subjects have not been conducted. It is recommended that doses of drugs with a vasopressive action, including dopaminergic agents, should be carefully titrated to achieve the desired response when co-administered with linezolid.</p><p>&nbsp;</p><p><em>Potential serotonergic interactions</em></p><p><em>&nbsp;</em></p><p>The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20 mg doses given 4 hours apart) with or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan.</p><p>&nbsp;</p><p>Post marketing experience: there has been one report of a patient experiencing serotonin syndrome- like effects while taking linezolid and dextromethorphan which resolved on discontinuation of both medications.</p><p>&nbsp;</p><p>During clinical use of linezolid with serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), cases of serotonin syndrome have been reported. Therefore, while co-administration is contraindicated (see section 4.3), management of patients for whom treatment with linezolid and serotonergic agents is essential, is described in section 4.4.</p><p>&nbsp;</p><p><em>Use with tyramine-rich foods</em></p><p><em>&nbsp;</em></p><p>No significant pressor response was observed in subjects receiving both linezolid and less than 100 mg tyramine. This suggests that it is only necessary to avoid ingesting excessive amounts of food and beverages with a high tyramine content (e.g. mature cheese, yeast extracts, undistilled alcoholic beverages and fermented soya bean products such as soy sauce).</p><p>&nbsp;</p><p><em>Drugs metabolised by cytochrome P450</em></p><p><em>&nbsp;</em></p><p>Linezolid is not detectably metabolised by the cytochrome P450 (CYP) enzyme system and it does not inhibit any of the clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Similarly, linezolid does not induce P450 isoenzymes in rats. Therefore, no CYP450-induced drug interactions are expected with linezolid.</p><p>&nbsp;</p><p><em>Rifampicin</em></p><p><em>&nbsp;</em></p><p>The effect of rifampicin on the pharmacokinetics of linezolid was studied in sixteen healthy adult male volunteers administered linezolid 600 mg twice daily for 2.5 days with and without rifampicin 600 mg once daily for 8 days. Rifampicin decreased the linezolid Cmax and AUC by a mean 21% [90% CI, 15, 27] and a mean 32% [90% CI, 27, 37], respectively. The mechanism of this interaction and its clinical significance are unknown.</p><p>&nbsp;</p><p><em>Warfarin</em></p><p><em>&nbsp;</em></p><p>When warfarin was added to linezolid therapy at steady-state, there was a 10% reduction in mean maximum INR on co-administration with a 5% reduction in AUC INR. There are insufficient data from patients who have received warfarin and linezolid to assess the clinical significance, if any, of these findings.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited data from the use of linezolid in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). A potential risk for humans exists.</p><p>Linezolid should not be used during pregnancy unless clearly necessary i.e. only if the potential benefit outweighs the theoretical risk.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breastfeeding should be discontinued prior to and throughout administration.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>In animal studies, linezolid caused a reduction in fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be warned about the potential for dizziness or symptoms of visual impairment (as described in section 4.4 and 4.8) whilst receiving linezolid and should be advised not to drive or operate machinery if any of these symptoms occurs.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The table below provides a listing of adverse drug reactions with frequency based on all-causality data from clinical studies that enrolled more than 2,000 adult patients who received the recommended linezolid doses for up to 28 days.</p><p>&nbsp;</p><p>Those most commonly reported were diarrhoea (8.4%), headache (6.5%), nausea (6.3%) and vomiting (4.0%).</p><p>&nbsp;</p><p>The most commonly reported drug-related adverse events which led to discontinuation of treatment were headache, diarrhoea, nausea and vomiting. About 3% of patients discontinued treatment because they experienced a drug-related adverse event.</p><p>&nbsp;</p><p>Additional adverse reactions reported from post-marketing experience are included in the table with frequency category &#39;Not known&#39;, since the actual frequency cannot be estimated from the available data.</p><p>&nbsp;</p><p>The following undesirable effects have been observed and reported during treatment with linezolid with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge;1/1,000</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare </strong><strong>(&lt;1/10,00 </strong><strong>0)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency not known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Candidiasis, oral candidiasis, vaginal candidiasis, fungal infections</p></td><td style="vertical-align:top"><p>Vaginitis</p></td><td style="vertical-align:top"><p>Antibiotic- associated colitis, including pseudomembrano us colitis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>anaemia*<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Leucopenia*, neutropenia, thrombocytopeni a*, eosinophilia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>pancytopenia*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myelosuppressio n*,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sideroblastic anaemia*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism </strong><strong>and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lactic acidosis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache, taste perversion (metallic taste), Dizziness</p></td><td style="vertical-align:top"><p>convulsions*, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Serotonin syndrome**, peripheral neuropathy*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blurred vision*</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>changes in visual field defect*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Optic neuropathy*, optic&nbsp;&nbsp;neuritis*, loss of vision*, changes in visual&nbsp;acuity*, changes in colour vision*.</p></td></tr><tr><td style="vertical-align:top"><strong>Ear&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and labyrinth disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Tinnitus</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Cardiac disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Arrhythmia (tachycardia)</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Vascular disorders</strong></td><td style="vertical-align:top">Hypertensi on</td><td style="vertical-align:top">Transient ischaemic attacks, phlebitis, thrombophlebitis</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Gastrointestin al disorders</strong></td><td style="vertical-align:top"><p>Diarrhoea, nausea, vomiting, localised or general abdominal pain, constipation</p>, dyspepsia</td><td style="vertical-align:top">Pancreatitis, gastritis, abdominal distention,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glossitis, loose&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stools, stomatitis, tongue discolouration or disorder</td><td style="vertical-align:top">Superficial tooth discolouration</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Hepato- biliary disorders</strong></td><td style="vertical-align:top"><p>Abnormal liver function test; increased AST,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ALT</p>or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alkaline phosphatase</td><td style="vertical-align:top">Increased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; total bilirubin</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Skin&nbsp;&nbsp;&nbsp; and subcutaneous tissue disorders</strong></td><td style="vertical-align:top">pruritus, rash</td><td style="vertical-align:top">Urticaria, dermatitis, diaphoresis,</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Bullous disorders such&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; those described&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as Stevens-Johnson syndrome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and toxic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epidermal necrolysis, angioedema, alopecia</td></tr><tr><td style="vertical-align:top"><strong>Renal&nbsp; and urinary disorders</strong></td><td style="vertical-align:top">Increased BUN</td><td style="vertical-align:top">Renal&nbsp;&nbsp; failure , Polyuria, increased creatinine</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Reproductive system and breast disorders</strong></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">Vulvovaginal disorder</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General </strong><strong>disorders and administratio n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site</strong></p><strong>conditions</strong></td><td style="vertical-align:top">fever, localised pain</td><td style="vertical-align:top">Chills, fatigue, injection site pain, increased thirst,</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><strong>Investigations</strong></td><td style="vertical-align:top"><p><u>Chemistry</u> Increased LDH,</p><p>creatine kinase, lipase, amylase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or non fasting glucose.</p><p>Decreased total protein, albumin, sodium&nbsp;&nbsp;&nbsp;&nbsp; or calcium.</p>Increased or decreased potassium or bicarbonate. <u>Haematolo</u> <u>gy</u> Increased neutrophils or eosinophils. Decreased haemoglobi n, haematocrit or red blood cell&nbsp; count. Increased or decreased platelet or white blood cell counts.</td><td style="vertical-align:top"><p><u>Chemistry</u> Increased sodium or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium. Decreased&nbsp;&nbsp;&nbsp;&nbsp; non fasting&nbsp;&nbsp;&nbsp; glucose. Increased&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or decreased chloride.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Haematology</u> Increased reticulocyte count.</p>Decreased neutrophils.</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>* See section 4.4.</p><p>** See sections 4.3 and 4.5</p><p>&dagger; See below</p><p>&nbsp;</p><p>The following adverse reactions to linezolid were considered to be serious in rare cases: localised abdominal pain, transient ischaemic attacks and hypertension.</p><p>&nbsp;</p><p>&dagger;In controlled clinical trials where linezolid was administered for up to 28 days, 2% of the patients reported anaemia. In a compassionate use program of patients with life-threatening infections and</p><p>&nbsp;</p><p>underlying co-morbidities, the percentage of patients who developed anaemia when receiving linezolid for &le; 28 days was 2.5% (33/1326) as compared with 12.3% (53/430) when treated for&gt;28 days. The proportion of cases reporting drug-related serious anaemia and requiring blood transfusion was 9% (3/33) in patients treated for &le; 28 days and 15% (8/53) in those treated for&gt;28 days.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Safety data from clinical studies based on more than 500 paediatric patients (from birth to 17 years) do not indicate that the safety profile of linezolid for paediatric patients differs from that for adult patients.</p><p>&nbsp;</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_2" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:137.4pt;margin-top:8.65pt;width:332.55pt;
  height:384.8pt;z-index:-15728640;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:.05in;margin-right:79.25pt;
     margin-bottom:0in;margin-left:.1in;margin-bottom:.0001pt;text-indent:87.75pt'><b
     style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
     mso-bidi-font-size:11.0pt;color:black;background:yellow'>To<span
     style='letter-spacing:-.5pt'> </span>report<span style='letter-spacing:
     -.5pt'> </span>any<span style='letter-spacing:-.5pt'> </span>side<span
     style='letter-spacing:-.55pt'> </span>effect(s):</span></b><b
     style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;
     mso-bidi-font-size:11.0pt;color:black'> <span style='background:yellow'>For
     Saudi Arabia:</span></span></b><b style='mso-bidi-font-weight:normal'><span
     style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></b></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:79.25pt;
     margin-bottom:0in;margin-left:.1in;margin-bottom:.0001pt;line-height:115%'><span
     style='color:black;background:yellow'>The<span style='letter-spacing:-.55pt'>
     </span>National<span style='letter-spacing:-.45pt'> </span>Pharmacovigilance<span
     style='letter-spacing:-.5pt'> </span>Centre<span style='letter-spacing:
     -.55pt'> </span>(NPC):</span><span style='color:black'> <span
     style='background:yellow'>SFDA Call Center: 19999.</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:139.15pt;
     margin-bottom:0in;margin-left:.1in;margin-bottom:.0001pt;line-height:115%'><a
     href="mailto:npc.drug@sfda.gov.sa"><span style='color:black;background:
     yellow;text-decoration:none;text-underline:none'>E-mail: </span><span
     style='color:black;background:yellow'>npc.drug@sfda.gov.sa</span></a><span
     style='color:black'> <span style='background:yellow'>Website:<span
     style='letter-spacing:-.1pt'> <u>https://ade.sfda.gov.sa</u></span></span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.3pt'><span style='font-size:13.5pt;
     mso-bidi-font-size:12.0pt'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal style='margin-left:.1in'><b style='mso-bidi-font-weight:
     normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;
     color:black;background:yellow'>For<span style='letter-spacing:-.1pt'> </span><span
     style='letter-spacing:-.2pt'>UAE:</span></span></b><b style='mso-bidi-font-weight:
     normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></b></p>
     <p class=MsoBodyText style='margin-left:.1in'><span style='color:black;
     background:yellow'>Pharmacovigilance<span style='letter-spacing:-.25pt'> </span>&amp;<span
     style='letter-spacing:-.1pt'> </span>Medical<span style='letter-spacing:
     -.1pt'> </span>Device<span style='letter-spacing:-.1pt'> section</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.15pt;margin-right:0in;margin-bottom:
     0in;margin-left:.1in;margin-bottom:.0001pt'><span style='color:black;
     background:yellow'>P.O. Box: <span style='letter-spacing:-.2pt'>1853</span><span
     style='letter-spacing:2.0pt'> </span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:.1in;margin-bottom:.0001pt'><span style='color:black;
     background:yellow'>Tel:<span style='letter-spacing:-.1pt'> 80011111</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.05pt;margin-right:198.95pt;
     margin-bottom:0in;margin-left:.1in;margin-bottom:.0001pt;line-height:115%'><a
     href="mailto:pv@mohap.gov.ae"><span style='color:black;background:yellow;
     text-decoration:none;text-underline:none'>Email:<span style='letter-spacing:
     -.75pt'> </span></span><span style='color:black;background:yellow'>pv@mohap.gov.ae</span></a><span
     style='color:black'> <span style='background:yellow'>Drug Department</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:139.15pt;
     margin-bottom:0in;margin-left:.1in;margin-bottom:.0001pt;line-height:115%'><span
     style='color:black;background:yellow'>Ministry<span style='letter-spacing:
     -.5pt'> </span>of<span style='letter-spacing:-.55pt'> </span>Health<span
     style='letter-spacing:-.5pt'> </span>&amp;<span style='letter-spacing:
     -.5pt'> </span>Prevention,</span><span style='color:black'> <span
     style='letter-spacing:-.1pt;background:yellow'>Dubai</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:.1in;line-height:11.7pt;
     mso-line-height-rule:exactly'><span style='color:black;background:yellow'>United<span
     style='letter-spacing:-.1pt'> </span>Arab<span style='letter-spacing:-.05pt'>
     </span><span style='letter-spacing:-.1pt'>Emirates</span></span><o:p></o:p></p>
     <p class=MsoBodyText><o:p>&nbsp;</o:p></p>
     <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:.1in;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:
     normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;
     color:black;background:yellow'>For<span style='letter-spacing:-.2pt'> </span><span
     style='letter-spacing:-.1pt'>OMAN</span></span></b><span style='font-size:
     12.0pt;mso-bidi-font-size:11.0pt;color:black;letter-spacing:-.1pt;
     background:yellow'>:</span><span style='font-size:12.0pt;mso-bidi-font-size:
     11.0pt'><o:p></o:p></span></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:6.7pt;margin-bottom:
     0in;margin-left:.1in;margin-bottom:.0001pt'><span style='color:black;
     background:yellow'>Department of Pharmacovigilance &amp; Drug Information</span><span
     style='color:black'> <span style='background:yellow'>Directorate<span
     style='letter-spacing:-.3pt'> </span>General<span style='letter-spacing:
     -.3pt'> </span>of<span style='letter-spacing:-.35pt'> </span>Pharmaceutical<span
     style='letter-spacing:-.25pt'> </span>Affairs<span style='letter-spacing:
     -.3pt'> </span>&amp;<span style='letter-spacing:-.2pt'> </span>Drug<span
     style='letter-spacing:-.35pt'> </span>Control</span> <span
     style='background:yellow'>Ministry of Health, Sultanate of Oman</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:.1in'><span style='color:black;
     background:yellow'>Phone<span style='letter-spacing:-.15pt'> </span>Nos.
     22357687 / <span style='letter-spacing:-.1pt'>22357686</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:.1in'><span style='color:black;
     background:yellow'>Fax:<span style='letter-spacing:-.25pt'> </span><span
     style='letter-spacing:-.1pt'>22358489</span></span><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:178.95pt;
     margin-bottom:0in;margin-left:.1in;margin-bottom:.0001pt'><a
     href="mailto:dg-padc@moh.gov.om"><span style='color:black;background:yellow;
     text-decoration:none;text-underline:none'>Email:<span style='letter-spacing:
     -.75pt'> </span></span><span style='color:black;background:yellow'>dg-padc@moh.gov.om</span></a><span
     style='color:black'> <span style='background:yellow'>Website: </span></span><a
     href="http://www.moh.gov.om/"><span style='color:black;background:yellow;
     text-decoration:none;text-underline:none'>www.moh.gov.om</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong><strong> For Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC): SFDA Call Center: 19999.</p><p>E-mail: npc.drug@sfda.gov.sa Website: <u>https://ade.sfda.gov.sa</u></p><p>&nbsp;</p><p><strong>For UAE:</strong></p><p>Pharmacovigilance &amp; Medical Device section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae Drug Department</p><p>Ministry of Health &amp; Prevention, Dubai</p><p>United Arab Emirates</p><p>&nbsp;</p><p><strong>For OMAN</strong>:</p><p>Department of Pharmacovigilance &amp; Drug Information Directorate General of Pharmaceutical Affairs &amp; Drug Control Ministry of Health, Sultanate of Oman</p><p>Phone Nos. 22357687 / 22357686</p><p>Fax: 22358489</p><p>Email: dg-padc@moh.gov.om Website: www.moh.gov.om</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific antidote is known.</p><p>&nbsp;</p><p>No cases of overdose have been reported. However, the following information may prove useful: Supportive care is advised together with maintenance of glomerular filtration. Approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, but no data are available for the removal of linezolid by peritoneal dialysis or haemoperfusion. The two primary metabolites of linezolid are also removed to some extent by haemodialysis.</p><p>Signs of toxicity in rats following doses of 3000 mg/kg/day linezolid were decreased activity and ataxia whilst dogs treated with 2000 mg/kg/day experienced vomiting and tremors.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antibacterials, ATC code: J01XX08</p><p>&nbsp;</p><p>General Properties</p><p>Linezolid is a synthetic, antibacterial agent that belongs to a new class of antimicrobials, the oxazolidinones. It has in vitro activity against aerobic Gram positive bacteria and anaerobic micro- organisms. Linezolid selectively inhibits bacterial protein synthesis via a unique mechanism of action. Specifically, it binds to a site on the bacterial ribosome (23S of the 50S subunit) and prevents the formation of a functional 70S initiation complex which is an essential component of the translation process.</p><p>&nbsp;</p><p>The in vitro postantibiotic effect (PAE) of linezolid for <em>Staphylococcus aureus </em>was approximately 2 hours. When measured in animal models, the in vivo PAE was 3.6 and 3.9 hours for <em>Staphylococcus aureus </em>and <em>Streptococcus pneumoniae, </em>respectively. In animal studies, the key pharmacodynamic parameter for efficacy was the time for which the linezolid plasma level exceeded the minimum inhibitory concentration (MIC) for the infecting organism.</p><p>&nbsp;</p><p>Breakpoints</p><p><strong><em>&nbsp;</em></strong></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for staphylococci and enterococci are Susceptible</p><p>&le; 4mg/L and Resistant&gt;4 mg/L. For streptococci (including <em>S. pneumoniae</em>) the breakpoints are Susceptible &le; 2 mg/L and Resistant&gt;4 mg/L.</p><p>&nbsp;</p><p>Non-species related MIC breakpoints are Susceptible &le; 2 mg/L and Resistant&gt; 4 mg/L. Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that have not been given a specific breakpoint and not for those species where susceptibility testing is not recommended.</p><p>&nbsp;</p><p><em><strong>Susceptibility</strong></em></p><p><strong><em>&nbsp;</em></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p><!--[if gte vml 1]><o:wrapblock pagebreak="t">
 <v:group id="Group_x0020_3" o:spid="_x0000_s1051" style='position:absolute;
  margin-left:58.9pt;margin-top:13.85pt;width:465.35pt;height:44.05pt;
  z-index:-15728128;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordsize="59099,5594" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Graphic_x0020_4" o:spid="_x0000_s1052" style='position:absolute;
   width:59010;height:584;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5901055,58419" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m5900661,12l9144,12,,,,9144,,57912r9144,l9144,9144r5891517,l5900661,12xe"
   fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_5" o:spid="_x0000_s1053" style='position:absolute;
   left:59006;width:95;height:584;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,58419" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m9143,l,,,57912r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_6" o:spid="_x0000_s1054" style='position:absolute;
   left:59006;width:95;height:95;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9143,l,,,9143r9143,l9143,xe" fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_7" o:spid="_x0000_s1055" style='position:absolute;
   left:45;top:106;width:58916;height:96;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5891530,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m5891530,l9144,,,,,9131r9144,l5891530,9131r,-9131xe" fillcolor="#9f9f9f"
   stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_8" o:spid="_x0000_s1056" style='position:absolute;
   left:58961;top:106;width:95;height:95;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9143,l,,,9143r9143,l9143,xe" fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_9" o:spid="_x0000_s1057" style='position:absolute;
   left:58961;top:106;width:95;height:95;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m9143,l,,,9143r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_10" o:spid="_x0000_s1058" style='position:absolute;
   left:45;top:198;width:59011;height:381;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5901055,38100" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m5900674,l,,,38099r5900674,l5900674,xe" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_11" o:spid="_x0000_s1059" style='position:absolute;
   left:45;top:2697;width:95;height:95;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9143,l,,,9144r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_12" o:spid="_x0000_s1060" style='position:absolute;
   left:45;top:2697;width:59011;height:95;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5901055,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m5900661,r-9131,l9144,,,,,9144r9144,l5891517,9144r9144,l5900661,xe"
   fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_13" o:spid="_x0000_s1061" style='position:absolute;
   left:45;top:198;width:95;height:2502;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,250190" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m9143,l,,,249935r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_14" o:spid="_x0000_s1062" style='position:absolute;
   top:198;width:59055;height:2591;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5905500,259079" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9144,38100l,38100,,259067r9144,l9144,38100xem5905233,r-9144,l5896089,249923r9144,l5905233,xe"
   fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_15" o:spid="_x0000_s1063" style='position:absolute;
   left:59006;top:579;width:95;height:2209;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,220979" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9143,l,,,220979r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_16" o:spid="_x0000_s1064" style='position:absolute;
   top:2788;width:95;height:477;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,47625" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA3iX1TwgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pi8Iw
EMXvgt8hjOBNU0XU7RpFBMXDXvwDXsdmtu3aTEoSbf32G0HwNsN7vzdvFqvWVOJBzpeWFYyGCQji
zOqScwXn03YwB+EDssbKMil4kofVsttZYKptwwd6HEMuYgj7FBUUIdSplD4ryKAf2po4ar/WGQxx
dbnUDpsYbio5TpKpNFhyvFBgTZuCstvxbmKNy/X8t/tiLy/1RDbXjbv/zGZK9Xvt+htEoDZ8zG96
ryM3hdcvcQC5/AcAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQA3iX1TwgAAANsAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" path="m9143,l,,,47243r9143,l9143,xe" fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_17" o:spid="_x0000_s1065" style='position:absolute;
   left:45;top:2788;width:59055;height:477;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5905500,47625" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m5891530,12l9144,12,,12,,9144r9144,l5891530,9144r,-9132xem5905233,r-9144,l5896089,47244r9144,l5905233,xe"
   fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_18" o:spid="_x0000_s1066" style='position:absolute;
   left:58961;top:2788;width:95;height:96;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m9143,l,,,9143r9143,l9143,xe" fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_19" o:spid="_x0000_s1067" style='position:absolute;
   left:58961;top:2788;width:95;height:96;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAy2obdwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Na8JA
EL0L/odlCr2ZTQsNaeoqRSnUo5q01yE7JrHZ2Zjdmuiv7xYEb/N4nzNfjqYVZ+pdY1nBUxSDIC6t
brhSkO8/ZikI55E1tpZJwYUcLBfTyRwzbQfe0nnnKxFC2GWooPa+y6R0ZU0GXWQ74sAdbG/QB9hX
Uvc4hHDTyuc4TqTBhkNDjR2taip/dr9Gwff6RRfHSm+u7pSnCRfJV1omSj0+jO9vIDyN/i6+uT91
mP8K/7+EA+TiDwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhADLaht3BAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" path="m9143,l,,,9143r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_20" o:spid="_x0000_s1068" style='position:absolute;
   left:45;top:2880;width:59011;height:381;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5901055,38100" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDfaHCKwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/LSsNA
FN0X+g/DFdw1kwbRkmYSpKUgujIt6PKSuXk0mTshM03j3zsLweXhvLNiMYOYaXKdZQXbKAZBXFnd
caPgcj5tdiCcR9Y4WCYFP+SgyNerDFNt7/xJc+kbEULYpaig9X5MpXRVSwZdZEfiwNV2MugDnBqp
J7yHcDPIJI6fpcGOQ0OLIx1aqvryZhS8b2db4VPdf92uLzZxpfw+fsxKPT4sr3sQnhb/L/5zv2kF
SVgfvoQfIPNfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAN9ocIrBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" path="m5900674,l,,,38099r5900674,l5900674,xe" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_21" o:spid="_x0000_s1069" style='position:absolute;
   left:45;top:5394;width:95;height:96;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m9143,l,,,9144r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_22" o:spid="_x0000_s1070" style='position:absolute;
   left:45;top:5394;width:59011;height:96;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5901055,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m5900661,r-9131,l9144,,,,,9144r9144,l5891517,9144r9144,l5900661,xe"
   fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_23" o:spid="_x0000_s1071" style='position:absolute;
   left:45;top:2880;width:95;height:2514;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="9525,251460" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9143,l,,,251459r9143,l9143,xe" fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_24" o:spid="_x0000_s1072" style='position:absolute;
   top:2880;width:59055;height:2718;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5905500,271780" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m9144,262140r-9144,l,271272r9144,l9144,262140xem9144,38100l,38100,,262128r9144,l9144,38100xem5905233,r-9144,l5896089,251460r9144,l5905233,xe"
   fillcolor="#efefef" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Graphic_x0020_25" o:spid="_x0000_s1073" style='position:absolute;
   top:3261;width:59099;height:2337;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5909945,233679" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m5909805,224040r-9144,l9144,224040r-9144,l,233172r9144,l5900661,233172r9144,l5909805,224040xem5909805,r-9144,l5900661,224028r9144,l5909805,xe"
   fillcolor="#9f9f9f" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Textbox_x0020_26" o:spid="_x0000_s1074" type="#_x0000_t202"
   style='position:absolute;left:137;top:3261;width:58826;height:2191;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA78FXlwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heYI33egh1OgqIhYKgjSmhx6f2WeymH0bs6um/75bKHgcZuYbZrXpbSMe1HnjWMFsmoAg
Lp02XCn4Kt4nbyB8QNbYOCYFP+Rhsx4OVphp9+ScHqdQiQhhn6GCOoQ2k9KXNVn0U9cSR+/iOosh
yq6SusNnhNtGzpMklRYNx4UaW9rVVF5Pd6tg+8353tyO58/8kpuiWCR8SK9KjUf9dgkiUB9e4f/2
h1YwT+HvS/wBcv0LAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAO/BV5cMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.05pt;margin-right:0in;margin-bottom:
      0in;margin-left:2.6pt;margin-bottom:.0001pt'><u><span style='font-size:
      12.0pt;mso-bidi-font-size:11.0pt'>Susceptible<span style='letter-spacing:
      -.1pt'> organisms</span></span></u><span style='font-size:12.0pt;
      mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Textbox_x0020_27" o:spid="_x0000_s1075" type="#_x0000_t202"
   style='position:absolute;left:137;top:525;width:58826;height:2172;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.25pt;margin-right:0in;margin-bottom:
      0in;margin-left:2.6pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:
      normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt;
      letter-spacing:-.1pt'>Category</span></b><b style='mso-bidi-font-weight:
      normal'><span style='font-size:12.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>Category</strong></p></td></tr><tr><td><p><u>Susceptible organisms</u></p><p><strong>Gram positive aerobes: </strong></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium* </em></p><p><em>Staphylococcus aureus </em>*</p><p>Coagulase negative staphylococci</p><p><em>Streptococcus agalactiae* </em></p><p>Streptococcus pneumoniae*</p><p><em>Streptococcus pyogenes*</em></p><p>Group C streptococci</p><p>Group G streptococci</p><p><strong>Gram positive anaerobes: </strong></p><p><em>Clostridium perfringens </em></p><p><em>Peptostreptococcus anaerobius </em></p><p><em>Peptostreptococcus </em>species</p></td></tr><tr><td><p><u>Resistant organisms</u></p><p><em>Haemophilus influenzae </em></p><p><em>Moraxella catarrhalis </em></p><p><em>Neisseria </em>species</p><p><em>Enterobacteriaceae </em></p><p><em>Pseudomonas </em>species</p></td></tr></tbody></table><p>&nbsp;</p><p><span style="text-align:unset">*Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications.</span></p><p>&nbsp;</p><p>Whereas linezolid shows some in vitro activity against <em>Legionella, Chlamydia pneumoniae </em>and <em>Mycoplasma pneumoniae</em>, there are insufficient data to demonstrate clinical efficacy.</p><p>&nbsp;</p><p>Resistance</p><p><strong><em>&nbsp;</em></strong></p><p><u>Cross resistance</u></p><p>Linezolid&#39;s mechanism of action differs from those of other antibiotic classes. In vitro studies with clinical isolates (including methicillin-resistant staphylococci, vancomycin-resistant enterococci, and penicillin- and erythromycin-resistant streptococci) indicate that linezolid is usually active against organisms which are resistant to one or more other classes of antimicrobial agents.</p><p>&nbsp;</p><p>Resistance to linezolid is associated with point mutations in the 23S rRNA.</p><p>&nbsp;</p><p>As documented with other antibiotics when used in patients with difficult to treat infections and/or for prolonged periods, emergent decreases in susceptibility have been observed with linezolid. Resistance to linezolid has been reported in enterococci, Staphylococcus aureus and coagulase negative staphylococci. This generally has been associated with prolonged courses of therapy and the presence of prosthetic materials or undrained abscesses. When antibiotic-resistant organisms are encountered in the hospital it is important to emphasize infection control policies.</p><p>&nbsp;</p><p>Information from clinical trials</p><p><strong><em>&nbsp;</em></strong></p><p>Studies in the paediatric population:</p><p>In an open study, the efficacy of linezolid (10 mg/kg q8h) was compared to vancomycin (10- 15mg/kg q6- 24h) in treating infections due to suspected or proven resistant gram-positive pathogens(including nosocomial pneumonia, complicated skin and skin structure infections,</p><p><br />catheter related bacteraemia, bacteraemia of unknown source, and other infections), in children from birth to 11 years. Clinical cure rates in the clinically evaluable population were 89.3% (134/150) and 84.5%(60/71) for linezolid and vancomycin, respectively (95%CI: -4.9, 14.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Kinzado primarily contains (s)-linezolid which is biologically active and is metabolised to form inactive derivatives.</p><p>&nbsp;</p><p>Absorption</p><p>Linezolid is rapidly and extensively absorbed following oral dosing. Maximum plasma concentrations are reached within 2 hours of dosing. Absolute oral bioavailability of linezolid (oral and intravenous dosing in a crossover study) is complete (approximately 100%). Absorption is not significantly affected by food and absorption from the oral suspension is similar to that achieved with the film-coated tablets.</p><p>&nbsp;</p><p>Plasma linezolid Cmax and Cmin (mean and [SD]) at steady-state following twice daily intravenous dosing of 600 mg have been determined to be 15.1 [2.5] mg/l and 3.68 [2.68] mg/l, respectively.</p><p>&nbsp;</p><p>In another study following oral dosing of 600 mg twice daily to steady-state, Cmax and Cmin were determined to be 21.2 [5.8] mg/l and 6.15 [2.94] mg/l, respectively. Steady-state conditions are achieved by the second day of dosing.</p><p>&nbsp;</p><p>Distribution</p><p>Volume of distribution at steady-state averages at about 40-50 litres in healthy adults and approximates to total body water. Plasma protein binding is about 31% and is not concentration dependent.</p><p>&nbsp;</p><p>Linezolid concentrations have been determined in various fluids from a limited number of subjects in volunteer studies following multiple dosing. The ratio of linezolid in saliva and sweat relative to plasma was 1.2:1.0 and 0.55:1.0, respectively. The ratio for epithelial lining fluid and alveolar cells of the lung was 4.5:1.0 and 0.15:1.0, when measured at steady-state Cmax, respectively. In a small study of subjects with ventricular-peritoneal shunts and essentially non-inflamed meninges, the ratio of linezolid in cerebrospinal fluid to plasma at Cmax was 0.7:1.0 after multiple linezolid dosing.</p><p>&nbsp;</p><p>Biotransformation</p><p><strong><em>&nbsp;</em></strong></p><p>Linezolid is primarily metabolised by oxidation of the morpholine ring resulting mainly in the formation of two inactive open-ring carboxylic acid derivatives; the aminoethoxyacetic acid metabolite (PNU-142300) and the hydroxyethyl glycine metabolite (PNU-142586). The hydroxyethyl glycine metabolite (PNU-142586) is the predominant human metabolite and is believed to be formed by a non-enzymatic process. The aminoethoxyacetic acid metabolite (PNU- 142300) is less abundant. Other minor, inactive metabolites have been characterised.</p><p>&nbsp;</p><p>Elimination</p><p>In patients with normal renal function or mild to moderate renal insufficiency, linezolid is primarily excreted under steady-state conditions in the urine as PNU-142586 (40%), parent drug (30%) and PNU-142300 (10%). Virtually no parent drug is found in the faeces whilst approximately 6% and 3% of each dose appears as PNU-142586 and PNU-142300, respectively. The elimination half-life of linezolid averages at about 5-7 hours.</p><p>&nbsp;</p><p>Non-renal clearance accounts for approximately 65% of the total clearance of linezolid. A small degree of non-linearity in clearance is observed with increasing doses of linezolid. This appears to be due to lower renal and non-renal clearance at higher linezolid concentrations. However, the difference in clearance is small and is not reflected in the apparent elimination half-life.</p><p>&nbsp;</p><p>Special Populations</p><p><strong><em>&nbsp;</em></strong></p><p><u>Renal impairment: </u>After single doses of 600 mg, there was a 7-8 fold increase in exposure to the two primary metabolites of linezolid in the plasma of patients with severe renal insufficiency (i.e. creatinine clearance &lt; 30 ml/min). However, there was no increase in AUC of parent drug. Although there is some removal of the major metabolites of linezolid by haemodialysis, metabolite plasma levels after single 600 mg doses were still considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.</p><p>&nbsp;</p><p>In 24 patients with severe renal insufficiency, 21 of whom were on regular haemodialysis, peak plasma concentrations of the two major metabolites after several days dosing were about 10 fold those seen in patients with normal renal function. Peak plasma levels of linezolid were not affected.</p><p>&nbsp;</p><p>The clinical significance of these observations has not been established as limited safety data are currently available (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Hepatic impairment: </u>Limited data indicate that the pharmacokinetics of linezolid, PNU-142300 and PNU-142586 are not altered in patients with mild to moderate hepatic insufficiency (i.e. Child-Pugh class A or B). The pharmacokinetics of linezolid in patients with severe hepatic insufficiency (i.e. Child-Pugh class C) have not been evaluated. However, as linezolid is metabolised by a non- enzymatic process, impairment of hepatic function would not be expected to significantly alter its metabolism (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><u>Paediatric population (&lt; 18 years old): </u>There are insufficient data on the safety and efficacy of linezolid in children and adolescents (&lt; 18 years old) and therefore, use of linezolid in this age group is not recommended. (see section 4.2). Further studies are needed to establish safe and effective dosage recommendations. Pharmacokinetic studies indicate that after single and multiple doses in children (1 week to 12 years), linezolid clearance (based on kg body weight) was greater in paediatric patients than in adults, but decreased with increasing age.</p><p>&nbsp;</p><p>In children 1 week to 12 years old, administration of 10 mg/kg every 8 hours daily gave exposure approximating to that achieved with 600 mg twice daily in adults.</p><p>&nbsp;</p><p>In neonates up to 1 week of age, the systemic clearance of linezolid (based on kg body weight) increases rapidly in the first week of life. Therefore, neonates given 10 mg/kg every 8 hours daily will have the greatest systemic exposure on the first day after delivery. However, excessive accumulation is not expected with this dosage regimen during the first week of life as clearance increases rapidly over that period.</p><p>&nbsp;</p><p>In adolescents (12 to 17 years old), linezolid pharmacokinetics were similar to that in adults following a 600 mg dose. Therefore, adolescents administered 600 mg every 12 hours daily will have similar exposure to that observed in adults receiving the same dosage.</p><p>&nbsp;</p><p>In paediatric patients with ventriculoperitoneal shunts who were administered linezolid 10 mg/kg either 12 hourly or 8 hourly, variable cerebrospinal fluid (CSF) linezolid concentrations were observed following either single or multiple dosing of linezolid. Therapeutic concentrations were</p><p>&nbsp;</p><p>not consistently achieved or maintained in the CSF. Therefore, the use of linezolid for the empirical treatment of paediatric patients with central nervous system infections is not recommended.</p><p>&nbsp;</p><p><u>Elderly patients</u>: The pharmacokinetics of linezolid are not significantly altered in elderly patients aged 65 and over.</p><p>&nbsp;</p><p><u>Female patients</u>: Females have a slightly lower volume of distribution than males and the mean clearance is reduced by approximately 20% when corrected for body weight. Plasma concentrations are higher in females and this can partly be attributed to body weight differences. However, because the mean half life of linezolid is not significantly different in males and females, plasma concentrations in females are not expected to substantially rise above those known to be well tolerated and, therefore, dose adjustments are not required.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Linezolid decreased fertility and reproductive performance of male rats at exposure levels approximately equal to those expected in humans. In sexually mature animals these effects were reversible. However, these effects did not reverse in juvenile animals treated with linezolid for nearly the entire period of sexual maturation. Abnormal sperm morphology in testis of adult male rats, and epithelial cell hypertrophy and hyperplasia in the epididymis were noted. Linezolid appeared to affect the maturation of rat spermatozoa. Supplementation of testosterone had no effect on linezolid-mediated fertility effects. Epididymal hypertrophy was not observed in dogs treated for 1 month, although changes in the weights of prostate, testes and epididymis were apparent.</p><p>&nbsp;</p><p>Reproductive toxicity studies in mice and rats showed no evidence of a teratogenic effect at exposure levels 4 times or equivalent, respectively, to those expected in humans. The same linezolid concentrations caused maternal toxicity in mice and were related to increased embryo death including total litter loss, decreased fetal body weight and an exacerbation of the normal genetic predisposition to sternal variations in the strain of mice. In rats, slight maternal toxicity was noted at exposures lower than expected clinical exposures. Mild fetal toxicity, manifested as decreased fetal body weights, reduced ossification of sternebrae, reduced pup survival and mild maturational delays were noted. When mated, these same pups showed evidence of a reversible dose-related increase in pre-implantation loss with a corresponding decrease in fertility. In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) at low exposure levels 0.06 times compared to the expected human exposure based on AUCs. The species is known to be sensitive to the effects of antibiotics.</p><p>&nbsp;</p><p>Linezolid and its metabolites are excreted into the milk of lactating rats and the concentrations observed were higher than those in maternal plasma.</p><p>&nbsp;</p><p>Linezolid produced reversible myelosuppression in rats and dogs.</p><p>&nbsp;</p><p>In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 of 3 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The optic nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change.</p><p>&nbsp;</p><p>&nbsp;</p><p>Preclinical data, based on conventional studies of repeated-dose toxicity and genotoxicity, revealed no special hazard for humans beyond those addressed in other sections of this Summary of Product Characteristics. Carcinogenicity / oncogenicity studies have not been conducted in view of the short duration of dosing and lack of genotoxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Internal Phase</strong></p><p>Kolliphor P 407 micro, &nbsp;Sodium Starch Glycollate, &nbsp;Povidone 30,</p><p>Colloidal Silicon Dioxide,</p><p>&nbsp;</p><p><strong>External Phase:</strong></p><p>Sodium Starch Glycollate, &nbsp;Avicel PH 102,</p><p>Lactose NF Fast Flow-BMS 35957, &nbsp;Purified Talc,</p><p>Magnesium Stearate.</p><p>&nbsp;</p><p><strong>Film-Coating: (Opadry II 33G28435 White)</strong></p><p>Hypromellose, Titanium&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dioxide, Polyethylene&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glycol/Macrogol, Lactose<br /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:481.7pt;height:13.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Monohydrate, Triacetin, Purified Water BP.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
Bottles:
Use within 100 days after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p><p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC -Aluminium foil blisters with 10 film-coated tablets 10 tablets/1 Blister).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
Al-Qassim Pharmaceutical Plant 
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>